Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.

ABSTRACT:

Purpose

Chordomas are rare and serious tumors with few effective treatments outside of aggressive surgery and radiation. Targeted therapies may present a more effective option for a subset of patients with lesions possessing certain genetic biomarkers.

Methods

A small molecule inhibitor library was tested in patient-derived UM-Chor1 cells to identify targeted therapies with potential efficacy. Targeted exome sequencing of UM-Chor1 and UM-Chor2 cells was performed to investigate genetic aberrations in relevant pathways. Chordoma cell lines were treated with inhibitors of the phosphotidylinositol 3-kinase (PI3K), epidermal growth factor receptor (EGFR), and cyclin dependent kinase (CDK) pathways, and responses were determined using resazurin cell viability assays, Annexin V ap

SUBMITTER: Michmerhuizen NL 

PROVIDER: S-EPMC7474463 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature